Recently, Yang et al evaluated GC samples from 148 patients and found a heterogeneity rate of 79.3% in human epithelial growth factor receptor 2 (HER2) protein overexpression and 44% in HER2 gene amplification [6]. This evidence concerns the gene ERBB2 and gastric cancer.